Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Genes Chromosomes Cancer ; 56(10): 719-729, 2017 10.
Article in English | MEDLINE | ID: mdl-28736828

ABSTRACT

Chromophobe renal cell carcinoma (ChRCC) represents 5% of all RCC cases and frequently demonstrates multiple chromosomal losses and an indolent pattern of local growth, but can demonstrate aggressive features and resistance to treatment in a metastatic setting. Cell line models are an important tool for the investigation of tumor biology and therapeutic drug efficacy. Currently, there are few ChRCC-derived cell lines and none is well characterized. This study characterizes a novel ChRCC-derived cell line model, UOK276. A large ChRCC tumor with regions of sarcomatoid differentiation was used to establish a spontaneously immortal cell line, UOK276. UOK276 was evaluated for chromosomal, mutational, and metabolic aberrations. The UOK276 cell line is hyperdiploid with a modal number of 49 chromosomes per cell, and evidence of copy-neutral loss of heterozygosity, as opposed to the classic pattern of ChRCC chromosomal losses. UOK276 demonstrated a TP53 missense mutation, expressed mutant TP53 protein, and responded to treatment with a small-molecule therapeutic agent, NSC319726, designed to reactivate mutated TP53. Xenograft tumors grew in nude mice and provide an in vivo animal model for the investigation of potential therapeutic regimes. The xenograft pathology and genetic analysis suggested that UOK276 was derived from the sarcomatoid region of the original tumor. In summary, UOK276 represents a novel in vitro and in vivo cell line model for aggressive, sarcomatoid-differentiated, TP53 mutant ChRCC. This preclinical model system could be used to investigate the novel biology of aggressive, sarcomatoid ChRCC and evaluate the new therapeutic regimes.


Subject(s)
Carcinoma, Renal Cell/genetics , Karyotype , Kidney Neoplasms/genetics , Tumor Suppressor Protein p53/metabolism , Animals , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Humans , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Male , Mice , Mice, Nude , Middle Aged , Mutation, Missense , Tumor Suppressor Protein p53/genetics
2.
Cancer Genet Cytogenet ; 180(2): 100-9, 2008 Jan 15.
Article in English | MEDLINE | ID: mdl-18206534

ABSTRACT

The establishment, characterization, and tumorigenicity of a new epithelial cell line (UOK 257) derived from human renal carcinoma of an individual with Birt-Hogg-Dubé (BHD) syndrome are reported. Unlike other established renal tumor cell lines from sporadic renal cell carcinoma, this is the first established renal tumor cell line of BHD, an inheritable neoplastic syndrome. The isolated tumor cells display loss of contact inhibition in vitro, and produce subcutaneous tumors in mouse xenografts. Histopathologic, ultrastructural, and cytogenetic characterizations of the established tumor cells are reported. Cytogenetic analysis using spectral karyotyping on UOK 257 cells revealed 17p loss and a near-triploid and aneuploid karyotype with multiple fluorescence in situ hybridization analysis using a locus-specific gene probe for MYC. The result demonstrates that the established tumor cells consist of two cell populations, one containing four and one containing five copies of the MYC oncogene.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Models, Biological , Proto-Oncogene Proteins/genetics , Tumor Suppressor Proteins/genetics , Carcinoma, Renal Cell/pathology , Cell Cycle/physiology , Cell Line, Tumor , Cell Proliferation , Chromosome Aberrations , Chromosomes, Human, Pair 17 , Gene Duplication , Genes, myc , Humans , Karyotyping , Kidney Neoplasms/pathology , Male , Middle Aged , Ploidies , Proto-Oncogene Proteins/physiology , Sequence Analysis, DNA , Signal Transduction/genetics , Syndrome , Tumor Suppressor Proteins/physiology
3.
J Endocrinol ; 193(2): 225-33, 2007 May.
Article in English | MEDLINE | ID: mdl-17470513

ABSTRACT

Phaeochromocytomas are rare neuroendocrine tumours that produce catecholamines and numerous secretory proteins and peptides, including neuropeptide Y (NPY), a vasoactive peptide with influences on blood pressure. The production of catecholamines and NPY by phaeochromocytomas is highly variable. This study examined influences of hereditary factors and differences in catecholamine production on tumour expression of NPY, as assessed by quantitative PCR, enzyme immunoassay and immunohistochemistry. Phaeochromocytomas included hereditary adrenaline-producing tumours (adrenergic phenotype) in multiple endocrine neoplasia type 2 (MEN 2), predominantly noradrenaline-producing tumours (noradrenergic phenotype) in von Hippel-Lindau (VHL) syndrome, and other adrenergic and noradrenergic tumours where there was no clear hereditary syndrome. NPY levels in phaeochromocytomas from VHL patients were lower (P<0.0001) than in those from MEN 2 patients for both mRNA (84-fold difference) and the peptide (99-fold difference). These findings were supported by immunohistochemistry. NPY levels were also lower in VHL tumours than in those where there was no hereditary syndrome. Relative absence of expression of NPY in phaeochromocytomas from VHL patients when compared with other groups appears to be largely independent of differences in catecholamine production and is consistent with a unique phenotype in VHL syndrome.


Subject(s)
Adrenal Gland Neoplasms/chemistry , Neuropeptide Y/analysis , Pheochromocytoma/chemistry , von Hippel-Lindau Disease/metabolism , Adult , Aged , Analysis of Variance , Female , Humans , Immunohistochemistry , Linear Models , Male , Middle Aged , Multiple Endocrine Neoplasia Type 2a/chemistry , Neuropeptide Y/genetics , Phenylethanolamine N-Methyltransferase/analysis , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction
4.
Eur J Endocrinol ; 153(4): 551-63, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16189177

ABSTRACT

OBJECTIVE: Phaeochromocytomas in patients with multiple endocrine neoplasia type 2 (MEN 2) produce adrenaline, whereas those with von Hippel-Lindau (VHL) syndrome do not. This study assessed whether these distinctions relate to differences in expression of the transporters responsible for uptake and storage of catecholamines - the noradrenaline transporter and the vesicular monoamine transporters (VMAT 1 and VMAT 2). METHODS: Tumour tissue and plasma samples were obtained from 31 patients with hereditary phaeochromocytoma - 18 with VHL syndrome and 13 with MEN 2. We used quantitative PCR, Western blotting, electron microscopy, immunohistochemistry and measurements of plasma and tumour catecholamines to assess differences in expression of the transporters in noradrenaline-producing vs adrenaline-producing hereditary tumours. These differences were compared with those in a further group of 26 patients with non-syndromic phaeochromocytoma. RESULTS: Adrenaline-producing phaeochromocytomas in MEN 2 patients expressed more noradrenaline transporter mRNA and protein than noradrenaline-producing tumours in VHL patients. In contrast, there was greater expression of VMAT 1 in VHL than MEN 2 tumours, while expression of VMAT 2 did not differ significantly. These differences were associated with larger numbers of storage vesicles and higher tissue contents of catecholamines in MEN 2 than in VHL tumours. Differences in expression of the noradrenaline transporter were weaker, and those of VMAT 1 and VMAT 2 stronger, in noradrenaline and adrenaline-producing non-syndromic than in hereditary tumours. CONCLUSIONS: The findings show that, in addition to differences in catecholamine biosynthesis, phaeochromocytomas in MEN 2 and VHL syndrome also differ in expression of the transporters responsible for uptake and vesicular storage of catecholamines.


Subject(s)
Adrenal Gland Neoplasms/etiology , Adrenal Gland Neoplasms/metabolism , Catecholamine Plasma Membrane Transport Proteins/metabolism , Multiple Endocrine Neoplasia Type 2a/complications , Pheochromocytoma/etiology , Pheochromocytoma/metabolism , von Hippel-Lindau Disease/complications , Adolescent , Adrenal Gland Neoplasms/pathology , Adult , Aged , Catecholamines/blood , Catecholamines/metabolism , Child , Female , Humans , Immunohistochemistry , Male , Microscopy, Electron , Middle Aged , Norepinephrine Plasma Membrane Transport Proteins/metabolism , Pheochromocytoma/pathology , Vesicular Biogenic Amine Transport Proteins/metabolism
5.
Clin Cancer Res ; 19(1): 42-9, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23136194

ABSTRACT

PURPOSE: Previous studies have shown that ischemia alters gene expression in normal and malignant tissues. There are no studies that evaluated effects of ischemia in renal tumors. This study examines the impact of ischemia and tissue procurement conditions on RNA integrity and gene expression in renal cell carcinoma. EXPERIMENTAL DESIGN: Ten renal tumors were resected without renal hilar clamping from 10 patients with renal clear cell carcinoma. Immediately after tumor resection, a piece of tumor was snap frozen. Remaining tumor samples were stored at 4°C, 22°C, and 37°C and frozen at 5, 30, 60, 120, and 240 minutes. Histopathologic evaluation was conducted on all tissue samples, and only those with greater than 80% tumor were selected for further analysis. RNA integrity was confirmed by electropherograms and quantitated using RNA integrity number index. Altered gene expression was assessed by paired, two-sample t test between the zero time point and aliquots from various conditions obtained from the same tumor. RESULTS: One hundred and forty microarrays were conducted. Some RNA degradation was observed 240 minutes after resection at 37°C. The expression of more than 4,000 genes was significantly altered by ischemia times or storage conditions. The greatest gene expression changes were observed with longer ischemia time and warmer tissue procurement conditions. CONCLUSION: RNA from kidney cancer remains intact for up to 4 hours post surgical resection regardless of storage conditions. Despite excellent RNA preservation, time after resection and procurement conditions significantly influence gene expression profiles. Meticulous attention to preacquisition variables is of paramount importance for accurate tumor profiling.


Subject(s)
Carcinoma, Renal Cell/genetics , Gene Expression Profiling , Ischemia , Kidney Neoplasms/genetics , Specimen Handling , Adult , Aged , Carcinoma, Renal Cell/blood supply , Carcinoma, Renal Cell/pathology , Gene Expression Regulation, Neoplastic , Humans , Kidney Neoplasms/blood supply , Kidney Neoplasms/pathology , Middle Aged , Neoplasm Staging , Reproducibility of Results , Temperature , Time Factors
6.
Cancer Res ; 69(11): 4674-81, 2009 Jun 01.
Article in English | MEDLINE | ID: mdl-19470766

ABSTRACT

Recent insights into the role of the von-Hippel Lindau (VHL) tumor suppressor gene in hereditary and sporadic clear-cell renal cell carcinoma (ccRCC) have led to new treatments for patients with metastatic ccRCC, although virtually all patients eventually succumb to the disease. We performed an integrated, genome-wide analysis of copy-number changes and gene expression profiles in 90 tumors, including both sporadic and VHL disease-associated tumors, in hopes of identifying new therapeutic targets in ccRCC. We identified 14 regions of nonrandom copy-number change, including 7 regions of amplification (1q, 2q, 5q, 7q, 8q, 12p, and 20q) and 7 regions of deletion (1p, 3p, 4q, 6q, 8p, 9p, and 14q). An analysis aimed at identifying the relevant genes revealed VHL as one of three genes in the 3p deletion peak, CDKN2A and CDKN2B as the only genes in the 9p deletion peak, and MYC as the only gene in the 8q amplification peak. An integrated analysis to identify genes in amplification peaks that are consistently overexpressed among amplified samples confirmed MYC as a potential target of 8q amplification and identified candidate oncogenes in the other regions. A comparison of genomic profiles revealed that VHL disease-associated tumors are similar to a subgroup of sporadic tumors and thus more homogeneous overall. Sporadic tumors without evidence of biallelic VHL inactivation fell into two groups: one group with genomic profiles highly dissimilar to the majority of ccRCC and a second group with genomic profiles that are much more similar to tumors with biallelic inactivation of VHL.


Subject(s)
Carcinoma, Renal Cell/genetics , Gene Dosage , Gene Expression Profiling , Kidney Neoplasms/genetics , von Hippel-Lindau Disease/genetics , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Comparative Genomic Hybridization , Gene Expression Regulation, Neoplastic , Gene Frequency , Genome-Wide Association Study , Humans , Kidney/pathology , Kidney Neoplasms/complications , Kidney Neoplasms/pathology , Neoplasm Metastasis , Polymorphism, Single Nucleotide , Von Hippel-Lindau Tumor Suppressor Protein/genetics , von Hippel-Lindau Disease/complications , von Hippel-Lindau Disease/pathology
7.
Evolution ; 39(1): 122-134, 1985 Jan.
Article in English | MEDLINE | ID: mdl-28563647

ABSTRACT

Extensive variation in the number of metacentric chromosomes exists among populations of the viviparous goodeid fish, Ilyodon furcidens, in the Río Coahuayana basin of south central Mexico (states of Colima and Jalisco). The variation can be divided, somewhat arbitrarily, into four "cytotypes" with 0-2, 0-4, 6 and 10-16 metacentrics. Of these, the first, shared with the closely adjacent Río Armería and similar to other species of Ilyodon, is probably ancestral. The wholly non-Robertsonian nature of the variation and its extent appear to be unprecedented among teleosts, but its uniqueness is difficult to evaulate because fish chromosome data in general may be biased toward both monomorphism and Robertsonian variation. Variation is evident with all cytotypes but has been well characterized for only a single population of the 0-4M cytotype. That population, unlike most of the others, consists of two interbreeding morphs which differ in mouth width. The variation is heterogeneously distributed between the morphs; the significance of this observation is not yet clear. The distribution of the cytotypes is approximately clinal with respect to the number of metacentric chromosomes. Although the cline may be a direct response to some gradient in selection intensity, the possibility that it is the result of secondary contact of previously isolated populations, fostered by tributary transfer, is real. Allozyme comparisons reveal minimal genic divergence among the cytotypes. There are no fixed allelic differences, and the average unbiased genetic distance between the two extreme cytotypes is 0.042. Gene diversity analysis indicates that an average of less than 3% of the total variation (HT = 0.072) is partitioned among cytotypes; about 24% is partitioned among populations within cytotypes. Genic and chromosomal divergence in Ilyodon are clearly uncoupled. Laboratory F1 , backcross, and F2 intercytotype hybrids are fully viable, and are indistinguishable in fertility from our stocks derived from single populations. F3 intercytotype hybrids are also fully viable but have not yet been tested for fertility. This suggests that, during the course of chromosomal evolution, single rearrangement heterozygotes were not appreciably negatively heterotic, even though the rearrangements are probably pericentric inversions. The combined data suggest that the chromosome rearrangements, even in multiple form, do not function as significant isolating mechanisms. Chromosomal evolution in Ilyodon, though quite marked, has apparently not fostered speciation.

8.
Proc Natl Acad Sci U S A ; 100(12): 6958-63, 2003 Jun 10.
Article in English | MEDLINE | ID: mdl-12777628

ABSTRACT

To identify potential molecular determinants of tumor biology and possible clinical outcomes, global gene-expression patterns were analyzed in the primary tumors of patients with metastatic renal cell cancer by using cDNA microarrays. We used grossly dissected tumor masses that included tumor, blood vessels, connective tissue, and infiltrating immune cells to obtain a gene-expression "profile" from each primary tumor. Two patterns of gene expression were found within this uniformly staged patient population, which correlated with a significant difference in overall survival between the two patient groups. Subsets of genes most significantly associated with survival were defined, and vascular cell adhesion molecule-1 (VCAM-1) was the gene most predictive for survival. Therefore, despite the complex biological nature of metastatic cancer, basic clinical behavior as defined by survival may be determined by the gene-expression patterns expressed within the compilation of primary gross tumor cells. We conclude that survival in patients with metastatic renal cell cancer can be correlated with the expression of various genes based solely on the expression profile in the primary kidney tumor.


Subject(s)
Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/secondary , Kidney Neoplasms/genetics , Kidney Neoplasms/mortality , Adult , Aged , Carcinoma, Renal Cell/genetics , Female , Gene Expression Profiling , Humans , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Prognosis , Survival Rate , United States/epidemiology , Vascular Cell Adhesion Molecule-1/genetics
SELECTION OF CITATIONS
SEARCH DETAIL